Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line

International Journal of Oncology

Volumn 33, Issue 5, 2008, Pages 1081-1089

  Chevrier, Lucie ^a   Meunier, Annie Claire ^a   Cochaud, Stéphanie ^a   Muller, Jean Marc ^a   Chadéneau, Corinne ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

Differentiation; MYCN; Neuroblastoma; Retinoic acid; Vasoactive intestinal peptide

Indexed keywords

ONCOPROTEIN; PROTEIN MYCN; RETINOIC ACID; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; HEAT SHOCK PROTEIN; MESSENGER RNA; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN; TP53INP1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL SHAPE; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; KINETICS; METABOLISM; NEUROBLASTOMA; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL SHAPE; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; KINETICS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS; TRETINOIN; VASOACTIVE INTESTINAL PEPTIDE;

EID: 58149182211     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000097     Document Type: Article

References (47)

1. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003.
2. Plantaz D: Neuroblastoma a century after Pepper: which are the genes? Arch Pediatr 8: 917-921, 2001.
3. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM: Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995, 1997.
4. Burkhart CA, Cheng AJ, Madafiglio J, et al: Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95: 1394-1403, 2003.
5. Ramsay G, Stanton L, Schwab M and Bishop JM: Human proto-oncogene N-myc encodes nuclear proteins that bind DNA. Mol Cell Biol 6: 4450-4457, 1986.
6. Wenzel A, Cziepluch C, Hamann U, Schürmann J and Schwab M: The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. EMBO J 10: 3703-3712, 1991.
7. Strieder V and Lutz W: Regulation of N-myc expression in development and disease. Cancer Lett 180: 107-119, 2002.
8. Muller JM, Lelievre V, Becq-Giraudon L and Meunier AC: VIP as cell growth and differentiation neuromodulator role in neurodevelopment. Mol Neurobiol 10: 115-134, 1995.
9. Grosfeld JL: Risk-based management of solid tumors in children. Am J Surg 180: 322-327, 2000.
10. Muller JM, Philippe M, Chevrier L, Héraud C, Alleaume C and Chadéneau C: The VIP-receptor system in neuroblastoma cells. Regul Pept 137: 34-41, 2006.
11. Agoston DV, Colburn S, Krajniak KG and Waschek JA: Distinct regulation of vasoactive intestinal peptide (VIP) expression at mRNA and peptide levels in human neuroblastoma cells. Neurosci Lett 139: 213-216, 1992.
12. Waschek JA, Muller JM, Duan DS and Sadée W: Retinoic acid enhances VIP receptor expression and responsiveness in human neuroblastoma cell, SH-SY5Y. FEBS Lett 250: 611-614, 1989.
13. Pence JC and Shorter NA: In vitro differentiation of human neuroblastoma cells caused by vasoactive intestinal peptide. Cancer Res 50: 5177-5183, 1990.
14. Hoshino M, Li M, Zheng LQ, Suzuki M, Mochizuki T and Yanaihara N: Pituitary adenylate cyclase activating peptide and vasoactive intestinal polypeptide: differentiation effects on human neuroblastoma NB-OK-1 cells. Neurosci Lett 159: 35-38, 1993.
15. Héraud C, Hilairet S, Muller JM, Leterrier JF and Chadéneau C: Neuritogenesis induced by vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and peptide histidine methionine in SH-SY5Y cells is associated with regulated expression of cytoskeleton mRNAs and proteins. J Neurosci Res 75: 320-329, 2004.
16. Hammerling U, Bjelfman C and Påhlman S: Different regulation of N- and c- myc expression during phorbol ester-induced maturation of human SH-SY5Y neuroblastoma cells. Oncogene 2: 73-77, 1987.
17. Kim SN, Kim SG, Park SD, Cho-Chung YS and Hong SH: Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells. J Cell Physiol 182: 421-428, 2000.
18. O'Dorisio MS, Fleshman DJ, Qualman SJ and O'Dorisio TM: Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma. Regul Pept 37: 213-226, 1992.
19. Grandinetti KB, Spengler BA, Biedler JL and Ross RA: Loss of one HuD allele on chromosome #1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells. Oncogene 25: 706-712, 2006.
20. Mayer C, Popanda O, Zelezny O, von Brevern MC, Bach A, Bartsch H and Schmezer P: DNA repair capacity after gamma-irradiation and expression profiles of DNA repair genes in resting and proliferating human peripheral blood lymphocytes. DNA Repair (Amst) 1: 237-250, 2002.
21. Harris RG, White E, Phillips ES and Lillycrop KA: The expression of the developmentally regulated proto-oncogene Pax-3 is modulated by N-Myc. J Biol Chem 277: 34815-34825, 2002.
22. Tonelli R, Purgato S, Camerin C, et al: Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol Cancer Ther 4: 779-786, 2005.
23. Manabe A, Iguchi-Ariga SM, Iizuka H and Ariga H: Transcriptional repression activity of N-MYC protein requires phosphorylation by MAP Kinase. Biochem Biophys Res Commun 219: 813-823, 1996.
24. Zaizen Y, Taniguchi S and Suita S: The role of cellular motility in the invasion of human neuroblastoma cells with or without N-myc amplification and expression. J Pediatr Surg 33: 1765-1770, 1998.
25. Chu PW, Cheung WM and Kwong YL: Differential effects of 9-cis, 13-cis and all-trans retinoic acids on the neuronal differentiation of human neuroblastoma cells. Neuroreport 14: 1935-1939, 2003.
26. Bell E, Lunec J and Tweddle DA: Cell cycle regulation targets of MYCN identified by gene expression microarrays. Cell Cycle 6: 1249-1256, 2007.
27. Thiele CJ, Reynolds CP and Israel MA: Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313: 404-406, 1985.
28. Han G, Chang B, Connor MJ and Sidell N: Enhanced potency of 9-cis versus all-trans-retinoic acid to induce differentiation of human neuroblastoma cells. Differentiation 59: 61-69, 1995.
29. Lovat PE, Lowis SP, Pearson AD, Malcolm AJ and Redfern CP: Concentration-dependent effects of 9-cis retinoic acid on neuroblastoma differentiation and proliferation in vitro. Neurosci Lett 182: 29-32, 1994.
30. Lovat PE, Irving H, Annicchiarico-Petruzzelli M, et al: Retinoids in neuroblastoma therapy: distinct biological properties of 9-cis- and all-trans-retinoic acid. Eur J Cancer 33: 2075-2080, 1997.
31. Joshi S, Guleria R, Pan J, DiPette D and Singh US: Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 25: 240-247, 2006.
32. Wang W, Nacusi L, Sheaff RJ and Liu X: Ubiquitination of p21Cip1/WAF1 by SCFSkp2: substrate requirement and ubiquitination site selection. Biochemistry 44: 14553-14564, 2005.
33. Tomasini R, Seux M, Nowak J, et al: TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 24: 8093-8104, 2005.
34. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A and Shohet JM: The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 102: 731-736, 2005.
35. Bell E, Premkumar R, Carr J, et al: The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle 5: 2639-2647, 2006.
36. Coffey DC, Kutko MC, Glick RD, et al: Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 35: 577-581, 2000.
37. Cetinkaya C, Hultquist A, Su Y, et al: Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells. Mol Cancer Ther 6: 2634-2641, 2007.
38. Goossens JF, Manechez D, Pommery N, Formstecher P and Hénichart JP: VIP potentiates retinoic-acid effect on tissue transglutaminase activity in human neuroblastoma, the SK-N-SH cells. Neuropeptides 24: 99-103, 1993.
39. Waschek JA, Lelievre V, Bravo DT, Nguyen T and Muller JM: Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines. Peptides 18: 835-841, 1997.
40. Balster DA, O'Dorisio MS, Albers AR, Park SK and Qualman SJ: Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1. Regul Pept 109: 155-165, 2002.
41. Maruno K, Absood A and Said SI: Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo. Proc Natl Acad Sci USA 24: 1473-1478, 1998.
42. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P and Bajo AM: Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. J Cancer Res Clin Oncol 27: 645-652, 2001.
43. Plonowski A, Varga JL, Schally AV, Krupa M, Groot K and Halmos G: Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. Int J Cancer 98: 624-629, 2002.
44. Levy A, Gal R, Granoth R, Dreznik Z, Fridkin M and Gozes I: In vitro and in vivo treatment of colon cancer by VIP antagonists. Regul Pept 109: 127-133, 2002.
45. Moody TW, Dudek J, Zakowicz H, et al: VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice. Life Sci 74: 1345-1357, 2004.
46. Moody TW, Leyton J, Chan D, et al: VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat 68: 55-64, 2001.
47. Gelber E, Granoth R, Fridkin M, Dreznik Z, Brenneman DE, Moody TW and Gozes I: A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer 92: 2172-2180, 2001.